Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data

Executive Summary

US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.

You may also be interested in...



FDA Pushing Forward With Withdrawal Of Two Concerta Generics

Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.

Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.

Track & Trace Requirement's Surprising Upside: Industry Efficiency

As November deadline looms, firms experience better receiving, communications thanks to upgrades, but FDA still waiting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel